To meet the unmet clinical treatment or prevention needs in major disease spectra such as infectious diseases, tumors, autoimmune diseases, and metabolism, while ensuring the success of our various products in terms of their pharmacological characteristics and competitive differentiation factors, Enno Biotech has, through several years of firm strategic implementation and research and development efforts, built a complete product development technology platform system that is industry-leading and covers the full range of mRNA technologies and elements. It has cumulatively filed over 310 global patents, extensively and deeply covering the core areas and key links of mRNA, possessing complete independent intellectual property rights, and has been recognized and verified for their pharmacological properties by major global regulatory systems such as NMPA, FDA, and TGA. Enno Biotech's mRNA full-chain and systematic technology platform provides a guarantee for enterprises to develop high-quality products with sufficient advantages to participate in global market competition. 

Through this highly efficient technology platform, Enno Biotech has successfully brought seven products with distinct competitive advantages to the approval for clinical trials or into the clinical stage. The products cover areas such as major infectious diseases,